SQ-Kyrin TMVr FIM Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Shenqi Medical Technology Co., Ltd

About this trial

A feasibility study to evaluate the effectiveness and safety of the SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System for the treatment of moderate-to-severe mitral regurgitation in patients with high surgical risk.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Severe mitral valve regurgitation ≥ 3+ (moderate-to-severe mitral regurgitation disease);

Porcelain aorta or active ascending aortic atheroma

Prior radiation therapy to mediastinum

History of mediastinitis

Disqualifiers

History of cardiac and mitral valve surgeries;

Infective endocarditis or evidence of active infection;

Mitral valve stenosis;

Severe uncontrolled coronary artery disease;

Trial design

Design model

Single group

Treatments tested in this trial

  • SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System

    Device

    Transesophageal echocardiography-guided, implantable mitral valve clip repair system

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: SQ-Kyrin TMVr Feasibility StudyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of acute procedural success

Must meet all the four items:1)no procedural mortality; 2)success in delivery and retrieval of the device delivery system; 3)successful deployment and accurate positioning of the device; 4)no emergency surgery or reintervention related to the device or surgical approach

Time frame
Immediate postoperative

Secondary outcomes

1

All-cause mortality

Death from any cause

Time frame
1 month
2

Incidence of serious adverse event(SAE)

If the adverse event meets any of the criteria below, it is regarded as a serious adverse event (SAE): 1) results in death; 2) is life threatening, results in illness or injury; 3) requires inpatient hospitalization or prolongation of existing hospitalization; 4) results in a persistent or significant disability/incapacity; 5) results in a congenital anomaly/birth defect, fetal death, fetal distress; 6) results in medical or surgical intervention to prevent permanent impairment to body structure or a body function; 7) an important medical event that may not result in death, be life-threatening, or require hospitalization but may be considered serious when, based upon appropriate medical judgment, may jeopardize the patient or subject and/or may require intervention to prevent one of the outcomes listed in this definition.

Time frame
1 month
3

Device success rate

Definition of device success(must meet all the four items) :1) No procedural mortality or stroke;2) Proper deployment and positioning of the device;3) No emergency surgery or reintervention related to the device or surgical approach;4) The implanted mitral valve repair system achieves the following safety and effectiveness indicators: * No evidence of structural or functional abnormality * No device-related technical failure or complication * Significant functional improvement after valve repair, without significant stenosis (post-op EOA ≥ 1.5 cm2 and transvalvular pressure gradient \< 5 mmHg/valve regurgitation ≤ Grade 2+/no device-related hemolysis)

Time frame
1 month
4

Procedural success rate

Definition of procedural success(must meet the two items):1) Device success;2) Absence of the following severe complications: death; stroke; life-threatening hemorrhage; severe vascular complications; secondary severe organic heart diseases (e.g.: aortic dissection, left atrium/auricle rupture, left ventricular outflow tract obstruction, etc.); Grade II-III and above renal insufficiency; myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); severe hypotension, heart failure, respiratory failure requiring use of high-dose vasoactive medications/mechanical acids; any valve-related dysfunctions, including repair device detachment (single or two valve leaflets)/embolism/device-related autologous mitral valve damage/other conditions requiring second intervention.

Time frame
1 month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.